fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ketoconazole

All products: general benefit

Teva-Ketoconazole · DIN 02231061 · 200 mg · tablet

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Teva-Ketoconazole · DIN 02231061 Manufacturer: Teva Canada Limited; listing date 2000-01-17 Daily cost (source): $0.9393 Health Canada: Marketed since 2014-03-29 · brand TEVA-KETOCONAZOLE · ATC J02AB02 KETOCONAZOLE · form Tablet · route Oral · ingredients KETOCONAZOLE 200 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Ketoconazole: Formulary list price $0.94 per unit (the source does not state the unit; exact figure $0.9393). What the ministry pays, not the patient.

Ministry pays: $0.9393 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231061)

Source record
DIN 02231061: Teva-Ketoconazole Raw flags: sec3=Y Item: 081204010; group id 12; item number 0015; lccId None; manufacturer id TEV Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.9393; ministry $0.9393 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231061 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50343 Therapeutic Notes (formulary) A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.
Interchangeable products
Apo-Ketoconazole · DIN 02237235 · $0.9393 Nizoral · DIN 00633836 · not recorded
Shortage status: shortage reported ended July 31, 2026 (report last updated July 31, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231061
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J02A): coverage varies; not interchangeable

  • Amphotericin b (Fungizone): general benefit
  • Fluconazole (Diflucan P.O.S.): general benefit, limited Use 528, not a benefit
  • Itraconazole (Sporanox): general benefit, limited Use 570, not a benefit
  • Voriconazole (Vfend): limited Use 399
  • Caspofungin (Cancidas): not a benefit
  • Micafungin (Mycamine): not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (12) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS For the treatment of serious or life-threatening systemic fungal infections in normal, predisposed or immunocompromised patients where alternate therapy is considered inappropriate or has been unsuccessful: systemic candidiasis, chronic mucocutaneous candidiasis, coccidioidomycosis and paracoccidioidomycosis, histoplasmosis and chromomycosis. Its use may also be considered in the treatment of severe, recalcitrant dermatophytoses unresponsive to other forms of therapy. The type of organism responsible for the infection should be identified; however, therapy may be initiated prior to obtaining these results, when clinically warranted. 1 Note: The treatment of fungal infections of the CNS is not recommended; ketoconazole penetrates poorly into the CNS. https://pdf.hres.ca/dpd_pm/00024529.PDF PM date: not printed or not captured Source product: TEVA-KETOCONAZOLE; DIN 02231061; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Ketoconazole · DIN 02231061 Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231061

Check this DIN again